Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sarah Goldberg MD, MPH

Sarah B. Goldberg MD, MPH

Associate Professor of Medicine (Medical Oncology), Yale School of Medicine/Yale Cancer Center, New Haven, Connecticut

Dr. Sarah Goldberg is an Associate Professor of Medicine in the division of Medical Oncology at the Yale School of Medicine and Yale Cancer Center. She specializes in the treatment of thoracic malignancies. Her research interests include personalized medicine and immunotherapy for non-small cell lung cancer and identification of biomarkers that predict response to treatment.


Dr. Sarah Goldberg reports receiving research funding from AstraZeneca, Boehringer Ingelheim, and Mirati.  Consulting/advisory board member for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Amgen, Blueprint Medicine, Sanofi Genzyme, Daiichi-Sankyo, Takeda, Janssen, Summit Therapeutics, Merck and Regeneron.